Altimmune Prices $225 Million Public Offering for Pemvidutide Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ALT?
Source: Newsfilter
- Offering Size: Altimmune announced the pricing of 64,250,000 shares of common stock at $3.00 per share, aiming to raise approximately $225 million, which underscores the company's fundraising capability and market confidence in its liver disease treatments.
- Warrant Details: Each accompanying warrant has an exercise price of $3.00, is immediately exercisable, and will expire 45 days after a successful Phase 3 trial data readout, indicating the company's confidence in its clinical trial outcomes.
- Use of Proceeds: The net proceeds from this offering will fund the upcoming Phase 3 trial in MASH and general working capital, reflecting the company's commitment to product development and responsiveness to market demands.
- Underwriter Arrangement: Leerink Partners and Barclays are acting as joint bookrunning managers for the offering, with Titan Partners as co-bookrunning manager, showcasing the company's strong network and resource integration capabilities in the capital markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALT
Wall Street analysts forecast ALT stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.410
Low
12.00
Averages
16.00
High
20.00
Current: 3.410
Low
12.00
Averages
16.00
High
20.00
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Altimmune Prices Oversubscribed Public Offering Raising $225 Million
- Funding Size: Altimmune successfully priced an oversubscribed public offering expected to raise approximately $225 million in gross proceeds, reflecting strong market demand for its stock and enhancing the company's financial capacity to support future R&D.
- Offering Details: The offering includes 64.25 million shares of common stock and pre-funded warrants to purchase up to 10.75 million shares of common stock, with each security accompanied by common stock warrants at an exercise price of $3.00 per share, providing investors with additional potential upside.
- Underwriter Role: Leerink Partners and Barclays acted as joint bookrunning managers for the offering, indicating confidence from these financial institutions in Altimmune and potentially paving the way for the company's future capital market activities.
- Market Reaction: Despite cautious sentiment regarding Altimmune's prospects, the successful financing demonstrates investor confidence in its potential products, particularly in the context of the company's plans for late-stage clinical trials.
See More
Altimmune Prices $225 Million Public Offering for Pemvidutide Development
- Offering Size: Altimmune announced the pricing of 64,250,000 shares of common stock at $3.00 per share, aiming to raise approximately $225 million, which underscores the company's fundraising capability and market confidence in its liver disease treatments.
- Warrant Details: Each accompanying warrant has an exercise price of $3.00, is immediately exercisable, and will expire 45 days after a successful Phase 3 trial data readout, indicating the company's confidence in its clinical trial outcomes.
- Use of Proceeds: The net proceeds from this offering will fund the upcoming Phase 3 trial in MASH and general working capital, reflecting the company's commitment to product development and responsiveness to market demands.
- Underwriter Arrangement: Leerink Partners and Barclays are acting as joint bookrunning managers for the offering, with Titan Partners as co-bookrunning manager, showcasing the company's strong network and resource integration capabilities in the capital markets.
See More
Concentrix and Altimmune Executives Increase Stock Holdings
- Concentrix CFO Purchase: Concentrix Corp's CFO Andre S. Valentine bought 2,500 shares of CNXC at $27.95 each, totaling $69,869, indicating confidence in the company's future performance.
- Trading Performance Review: Following Valentine's purchase, CNXC peaked at $29.94 during trading, reflecting a 7.1% increase from the purchase price, although it fell about 1% on Friday, highlighting market volatility.
- Altimmune Executive Trade: John Gill of Altimmune purchased 9,200 shares at $3.41 each on Monday, totaling $31,350, signaling his optimism about the company's prospects.
- Historical Trade Comparison: Prior to this purchase, Gill had bought 51,250 shares at $4.10 each over the past year, demonstrating his ongoing investment commitment to Altimmune, despite a 4.2% decline in stock price on Friday.
See More
ALT Stock Has Dropped Nearly 50% Over the Last Year, Yet Wall Street Predicts Nearly 500% Growth Potential.
Stock Price Target: The average 12-month price target for Altimmune (ALT) is $18, indicating a potential upside of 495% from its current trading level of $3.02.
Upcoming Trials: Altimmune is preparing to initiate a late-stage trial of pemvidutide for treating metabolic dysfunction-associated steatotic liver disease (MASLD) in 2026, with expectations to evaluate multiple doses over a 52-week treatment period.
Analyst Ratings: Among analysts covering Altimmune, nine have a 'Buy' or higher rating, while one has a 'Hold' and another a 'Sell' rating, reflecting a generally positive outlook despite recent stock performance.
Retail Sentiment: Retail sentiment around Altimmune's stock has shifted from 'bearish' to 'neutral' in the past 24 hours, although overall messaging volume remains low, indicating mixed investor confidence.
See More
AvaíBio Initiates α-Klotho Cell Bank Creation
- Key Milestone: AvaíBio, in collaboration with Austrianova, has initiated the creation of a Master Cell Bank (MCB) that overexpresses the α-Klotho protein, a process that clones a single genetically engineered cell into tens of millions of identical copies, establishing a foundation for future cell therapies and ensuring product consistency and scalability.
- Market Potential: The decline of α-Klotho protein is linked to various age-related diseases, with projections indicating that the Alzheimer's market alone could reach $32.8 billion by 2033, highlighting the significant demand for anti-aging treatments.
- Technological Advantage: The cell bank will utilize Austrianova's Cell-in-a-Box® technology, which allows therapeutic cells to continuously secrete proteins without triggering immune rejection, thereby enhancing the safety and efficacy of treatments.
- Dual-Program Strategy: AvaíBio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program using the same encapsulation technology, demonstrating the company's broad application potential in regenerative medicine and attracting institutional capital at unprecedented speed.
See More
AvaíBio Initiates Master Cell Bank for α-Klotho Production
- Critical Milestone: AvaíBio, in collaboration with Austrianova, has successfully initiated the creation of a Master Cell Bank (MCB) for α-Klotho protein, marking a significant advancement in the company's efforts to develop anti-aging therapies and laying a solid foundation for future cell therapy products.
- Massive Market Potential: With the Alzheimer's market projected to reach $32.8 billion by 2033, AvaíBio's technology is poised to play a crucial role in addressing this major health challenge, enhancing the company's market position in the biopharmaceutical sector.
- Technological Advantage: The Master Cell Bank will utilize Austrianova's Cell-in-a-Box® technology, ensuring that cells are protected within a biocompatible shell for continuous protein secretion without triggering immune rejection, thereby improving the safety and efficacy of treatments.
- Dual-Program Strategy: AvaíBio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program, leveraging the same encapsulation technology, showcasing the company's broad application potential in regenerative medicine and attracting significant institutional capital interest.
See More
Altimmune Prices Oversubscribed Public Offering Raising $225 Million
- Funding Size: Altimmune successfully priced an oversubscribed public offering expected to raise approximately $225 million in gross proceeds, reflecting strong market demand for its stock and enhancing the company's financial capacity to support future R&D.
- Offering Details: The offering includes 64.25 million shares of common stock and pre-funded warrants to purchase up to 10.75 million shares of common stock, with each security accompanied by common stock warrants at an exercise price of $3.00 per share, providing investors with additional potential upside.
- Underwriter Role: Leerink Partners and Barclays acted as joint bookrunning managers for the offering, indicating confidence from these financial institutions in Altimmune and potentially paving the way for the company's future capital market activities.
- Market Reaction: Despite cautious sentiment regarding Altimmune's prospects, the successful financing demonstrates investor confidence in its potential products, particularly in the context of the company's plans for late-stage clinical trials.
See More
Altimmune Prices $225 Million Public Offering for Pemvidutide Development
- Offering Size: Altimmune announced the pricing of 64,250,000 shares of common stock at $3.00 per share, aiming to raise approximately $225 million, which underscores the company's fundraising capability and market confidence in its liver disease treatments.
- Warrant Details: Each accompanying warrant has an exercise price of $3.00, is immediately exercisable, and will expire 45 days after a successful Phase 3 trial data readout, indicating the company's confidence in its clinical trial outcomes.
- Use of Proceeds: The net proceeds from this offering will fund the upcoming Phase 3 trial in MASH and general working capital, reflecting the company's commitment to product development and responsiveness to market demands.
- Underwriter Arrangement: Leerink Partners and Barclays are acting as joint bookrunning managers for the offering, with Titan Partners as co-bookrunning manager, showcasing the company's strong network and resource integration capabilities in the capital markets.
See More
Concentrix and Altimmune Executives Increase Stock Holdings
- Concentrix CFO Purchase: Concentrix Corp's CFO Andre S. Valentine bought 2,500 shares of CNXC at $27.95 each, totaling $69,869, indicating confidence in the company's future performance.
- Trading Performance Review: Following Valentine's purchase, CNXC peaked at $29.94 during trading, reflecting a 7.1% increase from the purchase price, although it fell about 1% on Friday, highlighting market volatility.
- Altimmune Executive Trade: John Gill of Altimmune purchased 9,200 shares at $3.41 each on Monday, totaling $31,350, signaling his optimism about the company's prospects.
- Historical Trade Comparison: Prior to this purchase, Gill had bought 51,250 shares at $4.10 each over the past year, demonstrating his ongoing investment commitment to Altimmune, despite a 4.2% decline in stock price on Friday.
See More
ALT Stock Has Dropped Nearly 50% Over the Last Year, Yet Wall Street Predicts Nearly 500% Growth Potential.
Stock Price Target: The average 12-month price target for Altimmune (ALT) is $18, indicating a potential upside of 495% from its current trading level of $3.02.
Upcoming Trials: Altimmune is preparing to initiate a late-stage trial of pemvidutide for treating metabolic dysfunction-associated steatotic liver disease (MASLD) in 2026, with expectations to evaluate multiple doses over a 52-week treatment period.
Analyst Ratings: Among analysts covering Altimmune, nine have a 'Buy' or higher rating, while one has a 'Hold' and another a 'Sell' rating, reflecting a generally positive outlook despite recent stock performance.
Retail Sentiment: Retail sentiment around Altimmune's stock has shifted from 'bearish' to 'neutral' in the past 24 hours, although overall messaging volume remains low, indicating mixed investor confidence.
See More
AvaíBio Initiates α-Klotho Cell Bank Creation
- Key Milestone: AvaíBio, in collaboration with Austrianova, has initiated the creation of a Master Cell Bank (MCB) that overexpresses the α-Klotho protein, a process that clones a single genetically engineered cell into tens of millions of identical copies, establishing a foundation for future cell therapies and ensuring product consistency and scalability.
- Market Potential: The decline of α-Klotho protein is linked to various age-related diseases, with projections indicating that the Alzheimer's market alone could reach $32.8 billion by 2033, highlighting the significant demand for anti-aging treatments.
- Technological Advantage: The cell bank will utilize Austrianova's Cell-in-a-Box® technology, which allows therapeutic cells to continuously secrete proteins without triggering immune rejection, thereby enhancing the safety and efficacy of treatments.
- Dual-Program Strategy: AvaíBio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program using the same encapsulation technology, demonstrating the company's broad application potential in regenerative medicine and attracting institutional capital at unprecedented speed.
See More
AvaíBio Initiates Master Cell Bank for α-Klotho Production
- Critical Milestone: AvaíBio, in collaboration with Austrianova, has successfully initiated the creation of a Master Cell Bank (MCB) for α-Klotho protein, marking a significant advancement in the company's efforts to develop anti-aging therapies and laying a solid foundation for future cell therapy products.
- Massive Market Potential: With the Alzheimer's market projected to reach $32.8 billion by 2033, AvaíBio's technology is poised to play a crucial role in addressing this major health challenge, enhancing the company's market position in the biopharmaceutical sector.
- Technological Advantage: The Master Cell Bank will utilize Austrianova's Cell-in-a-Box® technology, ensuring that cells are protected within a biocompatible shell for continuous protein secretion without triggering immune rejection, thereby improving the safety and efficacy of treatments.
- Dual-Program Strategy: AvaíBio is advancing both the Klothonova anti-aging platform and the Insulinova diabetes program, leveraging the same encapsulation technology, showcasing the company's broad application potential in regenerative medicine and attracting significant institutional capital interest.
See More
